Market Cap€95.9m

Last Close €13.86

Adocia is a French biotech company focused on innovative formulations of approved proteins. The company features the BioChaperone technology platform, which has generated six products in clinical stage; the most advanced is BioChaperone Lispro, which is Phase III ready. Adocia has four preclinical products; three are due to start clinical trials in 2018.

More Adocia content >

Investment summary

FY18 accounts show cash of €39.8m after the April 2018 payment of €37.2m ($50m) for the deal with Tonghua Dongbao (THDB) in China. The €11.9m 2018 arbitration award ($11.6m plus $1.6m interest) against Lilly should be received in 2019 after further legal aspects are cleared. A successful single-dose Phase I of BioChaperone (BC) pramlintide insulin could lead to a multiple-dose study in Q219. A European/US Phase III of BC Lispro can be run after a short bridging study and if a partner is found.

Content on Adocia
Adocia – Chinese progress and US lawyers
Healthcare | Update | 19 March 2019
test tube close up
Adocia – First arbitration won; partners sought
Healthcare | Update | 5 September 2018
test tube close up
Adocia – Pipeline and partnerships drive prospects
Healthcare | Initiation | 19 April 2018
test tube close up
View more
Share price graph
Price performance
Actual (2.4) 5.0 2.7
Relative* (3.4) (8.1) (0.4)
52-week high/low €20.7/€10.5
*% relative to local index
Key management
Gerard Soula CEO
Valerie Danaguezian CFO
Remi Soula Director of Business Development